<DOC>
	<DOCNO>NCT02557399</DOCNO>
	<brief_summary>This multicentre , randomize , single-blind ( investigator blind ) , active ( combination therapy adapalene [ ADA ] clindamycin [ CLDM ] ) -controlled parallel-group study Japanese subject facial acne vulgaris . The purpose study evaluate efficacy , safety tolerability CLDM 1 percent ( % ) -benzoyl peroxide 3 % ( Duac® : trademark own GlaxoSmithKline ) daily fix dose combination gel versus combination therapy ADA 0.1 % gel CLDM 1 % gel topical treatment facial acne vulgaris 12 week . A total 400 subject screen enrolment . Subjects use Duac® fix dose combination gel quantity sufficient cover entire face ( include forehead , nose , cheek chin ) daily even ( bedtime ) combination therapy ADA 0.1 % gel quantity sufficient cover entire face ( include forehead , nose , cheek chin ) daily even ( bedtime ) CLDM 1 % gel twice daily , morning evening ( bedtime ) 12 week .</brief_summary>
	<brief_title>DUAC® Early Onset Efficacy Study Japanese Subjects</brief_title>
	<detailed_description>Duac® register trademark Stiefel Laboratories , Inc. , GSK company . Duac® market Japan CLDM 1 % -benzoyl peroxide 3 % combination gel .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Male female subject 12 45 year age , inclusive . Subjects must : ( ) A minimum 17 60 ILs ( papule / pustule ) face , include nasal lesion ; ( b ) A minimum 20 150 nonILs ( open / close comedo ) face , include nasal lesion . Subjects ISGA score 2 great Baseline . Female subject childbearing potential woman le 2 year last menses must agree use contraception Subjects willing able follow study procedure visit schedule evaluation point . Subjects ability understand give write informed consent form ( write inform consent must obtain also parent guardian participant 20 year age ) . Subjects nodulocystic lesion Baseline . Female subject pregnant breastfeeding . Subjects history presence regional enteritis , inflammatory bowel disease ( e.g . ulcerative colitis , pseudomembranous colitis , chronic diarrhoea , antibioticassociated colitis bloody diarrhoea ) similar symptom . Subjects use follow agent within 2 week prior Baseline : topical antibiotic face systemic antibiotic ; topical antiacne medication ( e.g . Benzoyl peroxide , azelaic acid , resorcinol , salicylates etc . ) ; abradant , facial , peel , mask contain glycolic acid ; wash , soap , non mild facial cleanser contain benzoyl peroxide , salicylic acid sulfacetamide sodium ; moisturizers contain retinol , salicylic acid alpha betahydroxy acid ( except additive agent ) ; astringent toner . Subjects use follow agent face perform following procedure within 4 week prior baseline : topical corticosteroid apply onto face ( use inhale , intraarticular intralesional steroid facial acne acceptable ) ; facial procedure ( chemical laser peel , microdermabration , blue light treatment , etc. ) . Subjects use systemic retinoids within previous 6 month topical retinoids within 6 week prior Baseline . Subjects receive treatment estrogen , androgens antiandrogenic agent within previous 12 week ( subject treat agent 12 consecutive week prior start investigational product allow enrol long expect change dose , drug discontinue use study ) . Subjects use medication opinion investigator may affect clinical study evaluation study . Subjects plan use medication report exacerbate acne ( vitamin D vitamin B12 , corticosteroid , androgen , haloperidol , halogen , lithium , hydantoin Phenobarbital ) . Subjects know hypersensitivity previous allergic reaction component investigational product . Subjects use investigate therapy within previous 12 week plan participate another clinical study time . Subjects participate another Japanese clinical study plan GlaxoSmithKline K.K . development investigational product acne vulgaris . Subjects history substance abuse ( alcohol drug ) substance dependence within 12 month prior screen . Subjects medical history suggestive immunocompromized status . Subjects employee GlaxoSmithKline , investigator clinical research organization involve study immediate family member employee involve study . Subjects condition would put subject unacceptable risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Clindamycin</keyword>
	<keyword>Gel</keyword>
	<keyword>Benzoyl Peroxide</keyword>
	<keyword>Acne Vulgaris</keyword>
</DOC>